In Papua New Guinea, 1500+ women die every year from childbirth-related causes – 80 times higher than in Australia. And these deaths are, mostly, preventable.
Your support will help stop preventable deaths of mothers and babies in PNG
Globally, an estimated 36.7 million people were living with HIV, with 46 percent on life-saving antiretroviral treatment, according to the World Health Organization.
In Australia, more than 26,400 people were living with HIV in 2016 and according to annual HIV surveillance data more than 10 percent were unaware of their HIV-positive status.
The goals of our Eliminate HIV program include:
Deputy Program Director, Disease Elimination
A novel biomarker for gut leakage as a diagnostic tool for HIV disease progression
Investigating a novel plasma biomarker's potential for identifying gut leakage.
A novel gel for targeting vaginal inflammation to prevent HIV transmission
Developing an intravaginal gel delivering a vaginal microbiota metabolite.
ACCESS: STI and BBV surveillance system
ACCESS is a surveillance system that collates important information on a range of STIs and BBVs.
Antimicrobial and immune modulatory effects of vaginal microbiota metabolites
Determining the role of vaginal microbiota metabolites in activating HIV and other STIs.
Broadly neutralising anti-HIV antibodies and Fc Receptor function
Defining the properties of anti-HIV antibodies for vaccine development and protection of pregnant women.
co-EC Study: Eliminating hepatitis C/HIV coinfection
Eliminating hepatitis C transmission by enhancing care and treatment among HIV co-infected individuals.
Community-Based Rapid HIV Testing Services
Evaluating a multi-site rapid HIV testing trial in South Australia and rural site in Bendigo, Victoria.
DARE C: ATAHC II Substudy
DARE-C aims to evaluate therapy duration using triple therapy (PEG-IFN/RBV/TPV).
Decision science using Optima
Research and applications across disease areas to improve allocative efficiency.
Developing new HIV disease progression tests
This project will develop prognostic tools to identify HIV+ persons at risk of rapid disease progression.
Development of a novel prophylactic vaccine candidate for HIV-1
A prophylactic vaccine represents the best strategy for blocking HIV-1 transmission.
Development of hydrogel based intravaginal drug delivery device
Developing an intravaginal ring to deliver a microbiota metabolite.
HIV Prevention Cohort
Online cohort study of gay men in Victoria monitoring community-level change.
Impact of a vaginal microbiota metabolite on epithelium integrity and HIV susceptibility
Determining the role of a vaginal microbiota metabolite in enhancing the mucosal barrier to prevent HIV transmission.
Predicting quality and potency of monoclonal and natural antibodies
Rapid, simple and scalable assays for predicting antibody potency.
PrEPX: Rapid scale-up of HIV pre-exposure prophylaxis (PrEP)
Burnet is playing a crucial role in monitoring the outcomes of the PrEPX trial in Victoria.
PRONTO! Rapid HIV point-of-care testing in Victoria
The first rapid HIV test service in Victoria targeting gay men and men who have sex with men.
SHARP: Sexual Health And Risk Prevention Study
Assessing responses to HIV prevention measures among Australian MSM.
TAIPAN: HIV cascade surveillance
Internationally novel project to create a linked surveillance system to monitor the HIV cascade for gay men
Targeting novel sites on reverse transcriptase for HIV treatment and prevention
Discovering a new HIV drug class.
12 August, 2019
Burnet researchers among finalists for Research Australia Awards for innovative plasma separator, modelling tools.
25 July, 2019
The breadth of Burnet Institute’s HIV research has been impressively showcased at IAS 2019, in Mexico City.
04 September, 2019
Professor Mark Stoové is an organising committee member for the Contemporary Drug Problems Conference.
To achieve better health for vulnerable communities in Australia and internationally by accelerating the translation of research, discovery and evidence into sustainable health solutions.
85 Commercial Road, Melbourne
VIC, 3004, Australia
Receive updates and IMPACT magazine.
Copyright © 2019 Burnet Institute. ABN: 49 007 349 984
This website was developed with the generous support of a donor.
Burnet Institute (Australia) is located on the traditional land of the Boon Wurrung and Wurundjeri people and we offer our respects to the elders past and present.
We recognise and respect the cultural heritage of this land.
